Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Medivir AB ( (SE:MVIR) ) has shared an update.
Medivir AB, a Swedish specialty pharma player listed on Nasdaq Stockholm, is focused on innovative treatments for high unmet medical needs, led by its precision liver cancer therapy fostrox and MIV-711 for brittle bone disease. The company develops drugs in-house and through partnerships, targeting niche but potentially large-value indications for both patients and investors.
The company has appointed veteran finance executive Patrik Norgren as its new chief financial officer, effective March 23, succeeding long-serving CFO Magnus Christensen in a planned transition. With more than two decades of senior financial experience and a recent role as CFO at Cinclus Pharma, Norgren is expected to support Medivir’s ongoing transformation, leveraging its strengthened ownership base and solid financial position to drive long-term shareholder value.
Management highlights that the smooth handover and Norgren’s background in both private and listed pharmaceutical companies should bolster financial governance as Medivir’s key clinical projects progress. The move signals a sharpening of the company’s strategic and capital allocation capabilities at a pivotal stage, with implications for investors closely watching the advancement and potential monetization of its lead assets.
The most recent analyst rating on (SE:MVIR) stock is a Buy with a SEK54.00 price target. To see the full list of analyst forecasts on Medivir AB stock, see the SE:MVIR Stock Forecast page.
More about Medivir AB
Medivir AB is a Swedish pharmaceutical company listed on Nasdaq Stockholm’s Small Cap segment, focused on developing innovative therapies for diseases with high unmet medical need. Its lead programs include fostrox, a precision chemotherapy targeting liver cancer, and MIV-711 for Osteogenesis Imperfecta, both positioned as potential blockbuster treatments in markets with limited existing options.
The company pursues a partnership-driven business model, combining in-house drug development with collaborations to advance its pipeline. By concentrating on indications where current therapies are scarce or ineffective, Medivir aims to deliver significant clinical benefits for patients while creating substantial value for shareholders in specialized oncology and rare disease segments.
Average Trading Volume: 6,490,760
Technical Sentiment Signal: Sell
Current Market Cap: SEK778.9M
Learn more about MVIR stock on TipRanks’ Stock Analysis page.